Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report
Immune checkpoint inhibitors have taken an important place in the treatment of different types of malignancies. These drugs are known to have specific immune-mediated adverse events. We describe a case of severe nephrotic syndrome secondary to treatment with nivolumab in a patient with renal cell ca...
Gespeichert in:
| Veröffentlicht in: | Journal of immunotherapy (1997) 2017-11, Vol.40 (9), p.345-348 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 348 |
|---|---|
| container_issue | 9 |
| container_start_page | 345 |
| container_title | Journal of immunotherapy (1997) |
| container_volume | 40 |
| creator | Daanen, Robin A Maas, Rutger J H Koornstra, Rutger H T Steenbergen, Eric J van Herpen, Carla M L Willemsen, Annelieke E C A B |
| description | Immune checkpoint inhibitors have taken an important place in the treatment of different types of malignancies. These drugs are known to have specific immune-mediated adverse events. We describe a case of severe nephrotic syndrome secondary to treatment with nivolumab in a patient with renal cell carcinoma.
A 62-year-old man was treated with nivolumab for papillary renal cell carcinoma type 2 for 8 weeks when he was admitted to the hospital with a severe nephrotic syndrome and acute kidney injury. Renal biopsy showed focal segmental glomerulosclerosis. Treatment with high-dose corticosteroids had insufficient effect, but the addition of mycophenolate mofetil resulted in remission of the nephrotic syndrome and recovery of renal function. Proteinuria subsequently relapsed during corticosteroid tapering.
The time course in this patient strongly suggests that the nephrotic syndrome occurred as an adverse drug reaction to nivolumab treatment. If during nivolumab treatment renal insufficiency, hypoalbuminemia, or proteinuria develops, further analysis for a possible nephrotic syndrome is warranted for early detection and treatment of this life-threatening complication. |
| doi_str_mv | 10.1097/CJI.0000000000000189 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1945219390</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1945219390</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-e72d417ec4be6ece5b8df058810dbdc927bf8fd566a4bc47b6012fb91520b5ad3</originalsourceid><addsrcrecordid>eNpdUFtLwzAUDqK4Of0HInn0pTNJk7bxbQwvE5niBZ-k5HLKImszk1bYv7djU8TzcC6c7zuXD6FTSsaUyPxiejcbk79GC7mHhlSkecIFTfc3OeOJFCIfoKMYPwhhGePsEA1YITOakWKI3ufuyy-7WulExeiNUy1YPIfVIvjWGfy8bmzwNWDXYIUfVeugafGbaxf4CRq1xFNY9k4F4xpfq0s86YsIfXPlQ3uMDiq1jHCyiyP0en31Mr1N7h9uZtPJfWJSkrcJ5MxymoPhGjIwIHRhKyKKghKrrZEs11VRWZFlimvDc50Ryiot-_-IFsqmI3S-nbsK_rOD2Ja1i6a_TDXgu1hSyQWjMpWkh_It1AQfY4CqXAVXq7AuKSk3wpa9sOV_YXva2W5Dp2uwv6QfJdNvlrNzgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1945219390</pqid></control><display><type>article</type><title>Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Daanen, Robin A ; Maas, Rutger J H ; Koornstra, Rutger H T ; Steenbergen, Eric J ; van Herpen, Carla M L ; Willemsen, Annelieke E C A B</creator><creatorcontrib>Daanen, Robin A ; Maas, Rutger J H ; Koornstra, Rutger H T ; Steenbergen, Eric J ; van Herpen, Carla M L ; Willemsen, Annelieke E C A B</creatorcontrib><description>Immune checkpoint inhibitors have taken an important place in the treatment of different types of malignancies. These drugs are known to have specific immune-mediated adverse events. We describe a case of severe nephrotic syndrome secondary to treatment with nivolumab in a patient with renal cell carcinoma.
A 62-year-old man was treated with nivolumab for papillary renal cell carcinoma type 2 for 8 weeks when he was admitted to the hospital with a severe nephrotic syndrome and acute kidney injury. Renal biopsy showed focal segmental glomerulosclerosis. Treatment with high-dose corticosteroids had insufficient effect, but the addition of mycophenolate mofetil resulted in remission of the nephrotic syndrome and recovery of renal function. Proteinuria subsequently relapsed during corticosteroid tapering.
The time course in this patient strongly suggests that the nephrotic syndrome occurred as an adverse drug reaction to nivolumab treatment. If during nivolumab treatment renal insufficiency, hypoalbuminemia, or proteinuria develops, further analysis for a possible nephrotic syndrome is warranted for early detection and treatment of this life-threatening complication.</description><identifier>ISSN: 1524-9557</identifier><identifier>EISSN: 1537-4513</identifier><identifier>DOI: 10.1097/CJI.0000000000000189</identifier><identifier>PMID: 28961608</identifier><language>eng</language><publisher>United States</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Carcinoma, Renal Cell - drug therapy ; Drug Therapy, Combination ; Drug-Related Side Effects and Adverse Reactions - diagnosis ; Glomerulosclerosis, Focal Segmental ; Humans ; Immunosuppressive Agents - therapeutic use ; Kidney - physiology ; Kidney Neoplasms - drug therapy ; Male ; Middle Aged ; Mycophenolic Acid - therapeutic use ; Nephrotic Syndrome - diagnosis ; Nephrotic Syndrome - etiology ; Programmed Cell Death 1 Receptor - immunology ; Recovery of Function ; Recurrence</subject><ispartof>Journal of immunotherapy (1997), 2017-11, Vol.40 (9), p.345-348</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c307t-e72d417ec4be6ece5b8df058810dbdc927bf8fd566a4bc47b6012fb91520b5ad3</citedby><cites>FETCH-LOGICAL-c307t-e72d417ec4be6ece5b8df058810dbdc927bf8fd566a4bc47b6012fb91520b5ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28961608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daanen, Robin A</creatorcontrib><creatorcontrib>Maas, Rutger J H</creatorcontrib><creatorcontrib>Koornstra, Rutger H T</creatorcontrib><creatorcontrib>Steenbergen, Eric J</creatorcontrib><creatorcontrib>van Herpen, Carla M L</creatorcontrib><creatorcontrib>Willemsen, Annelieke E C A B</creatorcontrib><title>Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report</title><title>Journal of immunotherapy (1997)</title><addtitle>J Immunother</addtitle><description>Immune checkpoint inhibitors have taken an important place in the treatment of different types of malignancies. These drugs are known to have specific immune-mediated adverse events. We describe a case of severe nephrotic syndrome secondary to treatment with nivolumab in a patient with renal cell carcinoma.
A 62-year-old man was treated with nivolumab for papillary renal cell carcinoma type 2 for 8 weeks when he was admitted to the hospital with a severe nephrotic syndrome and acute kidney injury. Renal biopsy showed focal segmental glomerulosclerosis. Treatment with high-dose corticosteroids had insufficient effect, but the addition of mycophenolate mofetil resulted in remission of the nephrotic syndrome and recovery of renal function. Proteinuria subsequently relapsed during corticosteroid tapering.
The time course in this patient strongly suggests that the nephrotic syndrome occurred as an adverse drug reaction to nivolumab treatment. If during nivolumab treatment renal insufficiency, hypoalbuminemia, or proteinuria develops, further analysis for a possible nephrotic syndrome is warranted for early detection and treatment of this life-threatening complication.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Drug-Related Side Effects and Adverse Reactions - diagnosis</subject><subject>Glomerulosclerosis, Focal Segmental</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney - physiology</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Nephrotic Syndrome - diagnosis</subject><subject>Nephrotic Syndrome - etiology</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>Recovery of Function</subject><subject>Recurrence</subject><issn>1524-9557</issn><issn>1537-4513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUFtLwzAUDqK4Of0HInn0pTNJk7bxbQwvE5niBZ-k5HLKImszk1bYv7djU8TzcC6c7zuXD6FTSsaUyPxiejcbk79GC7mHhlSkecIFTfc3OeOJFCIfoKMYPwhhGePsEA1YITOakWKI3ufuyy-7WulExeiNUy1YPIfVIvjWGfy8bmzwNWDXYIUfVeugafGbaxf4CRq1xFNY9k4F4xpfq0s86YsIfXPlQ3uMDiq1jHCyiyP0en31Mr1N7h9uZtPJfWJSkrcJ5MxymoPhGjIwIHRhKyKKghKrrZEs11VRWZFlimvDc50Ryiot-_-IFsqmI3S-nbsK_rOD2Ja1i6a_TDXgu1hSyQWjMpWkh_It1AQfY4CqXAVXq7AuKSk3wpa9sOV_YXva2W5Dp2uwv6QfJdNvlrNzgw</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Daanen, Robin A</creator><creator>Maas, Rutger J H</creator><creator>Koornstra, Rutger H T</creator><creator>Steenbergen, Eric J</creator><creator>van Herpen, Carla M L</creator><creator>Willemsen, Annelieke E C A B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171101</creationdate><title>Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report</title><author>Daanen, Robin A ; Maas, Rutger J H ; Koornstra, Rutger H T ; Steenbergen, Eric J ; van Herpen, Carla M L ; Willemsen, Annelieke E C A B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-e72d417ec4be6ece5b8df058810dbdc927bf8fd566a4bc47b6012fb91520b5ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Drug-Related Side Effects and Adverse Reactions - diagnosis</topic><topic>Glomerulosclerosis, Focal Segmental</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney - physiology</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Nephrotic Syndrome - diagnosis</topic><topic>Nephrotic Syndrome - etiology</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>Recovery of Function</topic><topic>Recurrence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daanen, Robin A</creatorcontrib><creatorcontrib>Maas, Rutger J H</creatorcontrib><creatorcontrib>Koornstra, Rutger H T</creatorcontrib><creatorcontrib>Steenbergen, Eric J</creatorcontrib><creatorcontrib>van Herpen, Carla M L</creatorcontrib><creatorcontrib>Willemsen, Annelieke E C A B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of immunotherapy (1997)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daanen, Robin A</au><au>Maas, Rutger J H</au><au>Koornstra, Rutger H T</au><au>Steenbergen, Eric J</au><au>van Herpen, Carla M L</au><au>Willemsen, Annelieke E C A B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report</atitle><jtitle>Journal of immunotherapy (1997)</jtitle><addtitle>J Immunother</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>40</volume><issue>9</issue><spage>345</spage><epage>348</epage><pages>345-348</pages><issn>1524-9557</issn><eissn>1537-4513</eissn><abstract>Immune checkpoint inhibitors have taken an important place in the treatment of different types of malignancies. These drugs are known to have specific immune-mediated adverse events. We describe a case of severe nephrotic syndrome secondary to treatment with nivolumab in a patient with renal cell carcinoma.
A 62-year-old man was treated with nivolumab for papillary renal cell carcinoma type 2 for 8 weeks when he was admitted to the hospital with a severe nephrotic syndrome and acute kidney injury. Renal biopsy showed focal segmental glomerulosclerosis. Treatment with high-dose corticosteroids had insufficient effect, but the addition of mycophenolate mofetil resulted in remission of the nephrotic syndrome and recovery of renal function. Proteinuria subsequently relapsed during corticosteroid tapering.
The time course in this patient strongly suggests that the nephrotic syndrome occurred as an adverse drug reaction to nivolumab treatment. If during nivolumab treatment renal insufficiency, hypoalbuminemia, or proteinuria develops, further analysis for a possible nephrotic syndrome is warranted for early detection and treatment of this life-threatening complication.</abstract><cop>United States</cop><pmid>28961608</pmid><doi>10.1097/CJI.0000000000000189</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1524-9557 |
| ispartof | Journal of immunotherapy (1997), 2017-11, Vol.40 (9), p.345-348 |
| issn | 1524-9557 1537-4513 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1945219390 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adrenal Cortex Hormones - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - drug therapy Drug Therapy, Combination Drug-Related Side Effects and Adverse Reactions - diagnosis Glomerulosclerosis, Focal Segmental Humans Immunosuppressive Agents - therapeutic use Kidney - physiology Kidney Neoplasms - drug therapy Male Middle Aged Mycophenolic Acid - therapeutic use Nephrotic Syndrome - diagnosis Nephrotic Syndrome - etiology Programmed Cell Death 1 Receptor - immunology Recovery of Function Recurrence |
| title | Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T20%3A26%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nivolumab-associated%20Nephrotic%20Syndrome%20in%20a%20Patient%20With%20Renal%20Cell%20Carcinoma:%20A%20Case%20Report&rft.jtitle=Journal%20of%20immunotherapy%20(1997)&rft.au=Daanen,%20Robin%20A&rft.date=2017-11-01&rft.volume=40&rft.issue=9&rft.spage=345&rft.epage=348&rft.pages=345-348&rft.issn=1524-9557&rft.eissn=1537-4513&rft_id=info:doi/10.1097/CJI.0000000000000189&rft_dat=%3Cproquest_cross%3E1945219390%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1945219390&rft_id=info:pmid/28961608&rfr_iscdi=true |